Sign inCreate account

Report workspace

Add to folder
NCT05808673WITHDRAWNanonymous

A Randomized, Double-blind, Parallel Controlled, Phase I Three-arm Study, Comparing the PK, PD, Safety, and Immunogenicity of Pre- and Post-change CMAB807X, Post-change CMAB807X and Xgeva® in Healthy Chinese Male Subjects

Sponsor

Source record

Taizhou Mabtech Pharmaceutical Co.,Ltd

Phase

Source record

PHASE1

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Post-change CMAB807X, Pre-change CMAB807X, Xgeva®

Indication / condition

AI-normalized

Healthy Volunteers

Intervention

Source record

Post-change CMAB807X, Pre-change CMAB807X, Xgeva®

Related intelligence directories

Indication directory: Healthy VolunteersModality directory: monoclonal antibodyTarget directory: Post-change CMAB807X

Source & freshness

Source record

NCT ID

NCT05808673

Original source

ClinicalTrials.gov

Source last updated

Apr 09, 2024

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05808673

Title

A Randomized, Double-blind, Parallel Controlled, Phase I Three-arm Study, Comparing the PK, PD, Safety, and Immunogenicity of Pre- and Post-change CMAB807X, Post-change CMAB807X and Xgeva® in Healthy Chinese Male Subjects

Sponsor

Taizhou Mabtech Pharmaceutical Co.,Ltd

Status

WITHDRAWN

Phase

PHASE1

Condition raw

Healthy Volunteers

Condition normalized

Healthy Volunteers

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Post-change CMAB807X, Pre-change CMAB807X, Xgeva®

Target normalized

Post-change CMAB807X, Pre-change CMAB807X, Xgeva®

Interventions

Post-change CMAB807X, Pre-change CMAB807X, Xgeva®

Public preview

Source record

This is a randomized, double-blinded, controlled Phase I three-arms study of CMAB807X administered by subcutaneous injection. This study will characterize the pharmacokinetic, pharmacodynamics, safety and immunogenicity of CMAB807X Pre- and Post-change in Manufacturing Site, and Post-change CMAB807X versus Xgeva® #Denosumab# in healthy male subjects after a single dose

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Double-blind, Parallel Controlled, Phase I Three-arm Study, Comparing the PK, PD, Safety, and Immunogenicity of Pre- and Post-change CMAB807X, Post-change CMAB807X and Xgeva® in Healthy Chinese Male Subjects

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT05808673

Status

WITHDRAWN

Phase

PHASE1

Sponsor

Taizhou Mabtech Pharmaceutical Co.,Ltd

Executive brief

Investment-Ready Snapshot

This is a randomized, double-blinded, controlled Phase I three-arms study of CMAB807X administered by subcutaneous injection. This study will characterize the pharmacokinetic, pharmacodynamics, safety and immunogenicity of CMAB807X Pre- and Post-change in Manufacturing Site, and Post-change CMAB807X versus Xgeva® #Denosumab# in healthy male subjects after a single dose

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 09, 2024
Internal syncJun 18, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05808673

Indication

Healthy Volunteers

Modality

monoclonal antibody

Target

Post-change CMAB807X, Pre-change CMAB807X, Xgeva®

Intervention

Post-change CMAB807X, Pre-change CMAB807X, Xgeva®

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.